First Eagle Investment Management LLC Buys 273,044 Shares of Haleon PLC Sponsored ADR $HLN

First Eagle Investment Management LLC increased its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 9.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,056,951 shares of the company’s stock after buying an additional 273,044 shares during the quarter. First Eagle Investment Management LLC’s holdings in Haleon were worth $27,421,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its stake in Haleon by 107.6% in the second quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after acquiring an additional 1,410 shares during the last quarter. SOA Wealth Advisors LLC. raised its holdings in shares of Haleon by 60.5% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares during the period. Citizens National Bank Trust Department lifted its stake in Haleon by 167.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock valued at $29,000 after purchasing an additional 2,051 shares during the last quarter. Atlantic Union Bankshares Corp grew its holdings in Haleon by 293.7% during the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after purchasing an additional 2,758 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after buying an additional 1,203 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HLN. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Trading Down 1.7%

Shares of Haleon stock opened at $10.88 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The firm has a 50-day moving average of $10.47 and a 200-day moving average of $9.83. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42. The stock has a market cap of $48.45 billion, a PE ratio of 27.90 and a beta of 0.19.

Haleon Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio (DPR) is currently 61.54%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.